There were 428 press releases posted in the last 24 hours and 402,358 in the last 365 days.

Clinical Specialties Issues Voluntary Nationwide Recall of Avastin Unit Dose Syringes due to Potential Serious Eye Infection

Recall -- Firm Press Release

 

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

 

Clinical Specialties Issues Voluntary Nationwide Recall of Avastin Unit Dose Syringes due to Potential Serious Eye Infection

 

Contact: Consumer: Austin Gore 866-880-1915  

FOR IMMEDIATE RELEASE -March 18 , 2013 - Clinical Specialties is voluntarily recalling Avastin unit dose syringes.

The product has or potentially could result in an infection within the eye. Clinical Specialties has received reports of five intra-ocular infections from physician’s office and this is how the problem was identified.

This product was being used solely as an off label use by an ophthalmologist for macular degeneration and is packaged in sterile syringes. The affected product name lots are as follows:

Lot Number   Exp. Date   Lot Number   Exp. Date
CABDAHAC:39   5/8/2013   CABDACAB:56   4/2/2013
CABDAGAC:58   4/13/2013   CABDACAB:76   4/2/2013
CABDAHAC:77   4/8/2013   CABDACAB:89   4/2/2013
CABDBIAC:86   4/19/2013   CABDADAB:69   4/3/2013
CABDCFAC:29   4/26/2013   CABDADAB:93   4/3/2013
CABDAEAD:26   5/3/2013   CABDADAB:54   4/3/2013
CABDAEAC:47   5/5/2013   CABDAEAB:96   4/4/2013
CABDAEAC:58   5/5/2013   CABDAHAB:00   4/7/2013
CABDAFAC:46   5/6/2013   CABDAHAB:59   4/7/2013
CABDAIAC:46   5/9/2013   CABDAHAB:18   4/7/2013
CABDBCAC:94   5/13/2013   CABDAJAB:30   4/9/2013
CABDCCAC:26   5/23/2013   CABDAJAB:70   4/9/2013
CABDCFAC:81   5/26/2013   CABDAJAB:97   4/9/2013
CABDABAD:05   5/30/2013   CABDBAAB:63   4/10/2013
CABDAFAC:47   5/6/2013   CABDBAAB:77   4/10/2013
CABDAGAC:43   5/7/2013   CABDBAAB:54   4/10/2013
CABDBDAC:69   5/14/2013   CABDBAAB:04   4/10/2013
CABDBIAC:77   5/19/2013   CABDBEAB:97   4/14/2013
CABDCHAC:19   5/28/2013   CABDBFAB:67   3/16/2013
CABDAHAD:21   6/5/2013   CABDBFAB:61   4/15/2013
CABDCFAC:17   5/26/2013   CABDBFAB:84   4/15/2013
CABDAHAD:00   6/5/2013   CABDBGAB:34   4/16/2013
CABDBCAC:47   5/13/2013   CABDBHAB:33   4/17/2013
CABDCBAC:97   5/22/2013   CABDBHAB:71   4/17/2013
CABDAGAC:08   5/7/2013   CABDBHAB:75   4/17/2013
CABDBCAC:15   5/13/2013   CABDCBAB:66   4/21/2013
CABDBDAC:17   5/14/2013   CABDCCAB:64   4/22/2013
CABDCIAC:42   5/29/2013   CABDCDAB:38   4/23/2013
CABDBEAC:44   5/15/2013   CABDCEAB:71   4/24/2013
CABDCBAC:79   5/22/2013   CABDCEAB:04   4/24/2013
CABDCIAC:00   5/29/2013   CABDCFAB:22   3/26/2013
CABDAHAD:82   6/5/2013   CABDCFAB:14   4/25/2013
CABDCBAC:31   5/22/2013   CABDCIAB:51   4/28/2013
CABDCIAB:68   4/28/2013   CABDCIAB:93   3/29/2013
CABDCJAB:59   4/29/2013   CABDDBAB:71   4/1/2013
CABDDBAB:93   5/1/2013   CABCBJBC:00   3/19/2013
CABCCGBC:92   2/24/2013   CABCCGBC:30   3/26/2013
CABCCGBC:49   3/26/2013   CABCCHBC:55   3/27/2013
CABCCIBC:39   3/23/2013   CABCDBBC:87   3/31/2013
CABCDBBC:71   3/1/2013        

This product would be administered by a licensed physician in a surgery or physician’s office setting. The syringes were distributed to doctors’ offices in Georgia, Louisiana, South Carolina, and Indiana from December 18, 2012 to present.

Clinical Specialties has notified the physician’ offices by telephone. Doctors that have product which is being recalled should stop using the Avastin immediately.

Consumers with questions regarding this recall may contact Clinical Specialties by phone at 866.880.1915 or e-mail address at clinicalrx@bellsouth.net ; Monday through Friday between the hours of 10 am to 5 pm EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Online: www.fda.gov/medwatch/report.htm

Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Fax: 1-800-FDA-0178

###

RSS Feed for FDA Recalls Information [what's this?]

    

-

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.